Apogene

About Apogene

Apogene is building the next wave of diagnostic sequencing—simple kits and software that turn today’s research methods into actionable diagnostics. Our first product will deliver same-day, complete drug-resistance profiles from a single patient sample for high-impact infections—a step change from today’s fragmented, multi-day workflows. We are reducing: 1.) the time of genetic sequencing from 3 days to 1 workshift; 2.) the hands-on by a factor of 10X; and the cost by a factor of 8X. This same technology will power a dedicated cancer product for fast, routine testing.

Team

Christopher Cooney

Founder

Problem statement

Current genetic and infectious disease tests are either too limited in scope or take too long to deliver results. Our company addresses this gap by empowering routine clinical laboratories to conduct comprehensive testing on-site. This not only accelerates the delivery of actionable results but also boosts profit margins for smaller labs by eliminating the need for outsourcing.

Traction information

1.) The developments spin out of UC San Diego Medical School supported by a $3.6M R01 NIH grant intended to translate research into commercialization. The scientific reviewers gave it a score 1 point shy of the best possible score.
2.) Illumina, the leader in genetic sequencing with $4B in ARR, encouraged the founders to accelerate the translation of the technology.
3.) Illumina requested access to our Data Room and is considering a possible investment.

Updates

Profile created.

Added 15 days ago